Warnex signs up U.S. service lab, AmeriSci Bio-Chem
Warnex Inc. (TSX: WNX) announced today that AmeriSci Bio-Chem, a leading scientific service laboratory based in
Midlothian, Virginia, will offer real-time PCR pathogen testing services using the Warnex(TM) Rapid Pathogen Detection System. AmeriSci Bio-Chem will use Warnex’s food safety technology to test for strains of E. coli O157, Listeria and Salmonella.
AmeriSci Bio-Chem (www.ameriscibiochem.com) is a national independent third party laboratory that provides testing services in the areas of environmental microbiology, food safety, and molecular biology, with offices in Richmond, Boston, Manhattan, and Los Angeles. The company offers routine microbiology services to all food industries, including testing of raw ingredients, environmental samples, and finished products, providing clients
with effective data about their in-house quality and safety. With major accreditations from the American Association for Laboratory Accreditation (A2LA) and the American Industrial Hygiene Association (AIHA), AmeriSci Bio-Chem adheres to all FDA and USDA testing guidelines.
The Warnex Rapid Pathogen Detection System uses cutting-edge DNA-based technology to rapidly and accurately determine the presence of pathogens in a sample. The system allows for the simultaneous detection of multiple pathogens and processing of samples within 3 to 48 hours, a significant improvement over traditional microbiology tests that currently require 5 to 7 days.
About Warnex
Warnex (www.warnex.ca) is a biotechnology company devoted to protecting public health by providing advanced diagnostic products and science-based services to the agri-food, pharmaceutical and healthcare sectors. Warnex’s
genomics-based technology offers a versatile detection platform that produces accurate results rapidly, using Real-Time PCR technology combined with unique genetic markers and software. With a focus on pathogen detection in food, our development pipeline also includes applications in GMO testing, meat speciation, as well as in the detection of viruses, yeasts and moulds.
Warnex’s analytical, bioanalytical, and clinical service groups offer a variety of quality control services, method development and validation, contract R&D, bioavailability and bioequivalence studies for clinical trials, and medical laboratory testing.
For further information: please contact: Mark J. Busgang, President & CEO, Warnex Inc., Tel: (450) 663-6724 x.310, mbusgang@warnex.ca; Mike Polonsky, Investor Relations, The Equicom Group Inc., Tel: (416) 815-0700 x.231, mpolonsky@equicomgroup.com
